Atlas Trials

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Clinical trial NCT05736419 · RECRUITING

Trial details

NCT number
NCT05736419
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell DiseaseThalassemia, BetaThalassemia
Start date
2023-02-09
Primary completion
2027-02-09
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.